No Detail Found!

Computational Studies on Analogues of 8-Methoxy Derivatives of Fluoroquinolones as Potential Inhibitors of Mycobacterium Tuberculosis

Author(s)
Mahwish Akhtar Dow University of Health Sciences, Karachi, Pakistan.
Amna Iqbal Dow University of Health Sciences, Karachi, Pakistan.
Sabahat Abdullah University of Karachi, Karachi, Pakistan.
Moona Mehboob Khan Dow University of Health Sciences, Karachi, Pakistan.
Noor Jahan Dow University of Health Sciences, Karachi, Pakistan.
Mohammad Imran Iqra University of Health Sciences, Karachi, Pakistan.
Abstract
Aim and Objectives: This research study aims to find anti-tubercular agents using in-silico approaches. Background: Tuberculosis (TB) is an infectious disease primarily affecting the lungs, though it can spread to almost any tissue or organ in the body and is caused by Mycobacterium tuberculosis(Mtb), an acid-fast bacillus. While TB is typically chronic, persisting for months or even years, it can manifest in acute forms that may prove fatal within weeks or days if left untreated. Material and Methods: Moxifloxacin (MOX), a member of the fluoroquinolone class of antibiotics, was selected from the literature, and a library of compounds with 40% structural similarity was downloaded from ZINC database. The binding affinity (?G) of this generated library, consisting of 123 compounds, was analyzed using molecular docking with AutoDock-Vina, and the results were compared to the standard MOX. The top 16 compounds exhibiting excellent binding energies were further evaluated for drug-likeness and physicochemical properties using SwissADME and pkCSM tools. Results: The outcomes from the study revealed that the ?G values of all the compounds were superior to that of the MOX. Compound M110 exhibited the lowest ?G value of -19.5 kcal/mol. Additionally the selected compounds met all criteria for drug-likeness, physicochemical, pharmacokinetic, and toxicological parameters, indicating their potential as promising therapeutic candidates. Conclusion: The in-silico analysis concluded that all selected compounds demonstrated the potential to bind and inhibit DNA gyrase. Based on the findings, M110 shows considerable promise as a potent compound and requires further investigation in the drug development process for TB treatment.
Publication Details
Page(s) 25-49
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 3, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Moxifloxacin, Tuberculosis, Drug resistance, Pharmacokinetics, molecular docking
References
Chakaya J,Khan M,Ntoumi F,Aklillu E,Fatima R,Mwaba P .2021 .Reflections on the Global TB burden, treatment and prevention efforts. International journal of infectious diseases, 113 : S7-S12.
Fox W,Ellard GA,Mitchison DA .1999 .Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. The International Journal of Tuberculosis and Lung Disease, 3(10) : S231-S79.
Organization WH .2009 .Global tuberculosis control: epidemiology, strategy. financing: WHO report, : .
Feldman WH,Hinshaw HC .1948 .Streptomycin: a valuable anti-tuberculosis agent. British Medical Journal, 1(4541) : 87.
Szollosi DE .2023 .Antibiotic discoveries and a century of creating superbugs. , : .
Niyazi H. Investigating .2021 .the response of Mycobacterium tuberculosis to antituberculosis drugs: UCL. , : .
Shah AM,Shah SV .2024 .Recent advances in drug therapy for tuberculosis. National Journal of Physiology, Pharmacy and Pharmacology, 14(5) : 805-14.
Singh V,Chibale K. .2021 .Strategies to combat multi-drug resistance in tuberculosis. Accounts of chemical research, 54(10) : 2361-76.
van den Boogaard J,Kibiki GS,Kisanga ER,Boeree MJ,Aarnoutse RE .2009 .New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrobial agents and chemotherapy, 53(3) : 849-62.
Hofman S,Segers M,Ghimire S,Bolhuis M,Sturkenboom M,Van Soolingen D .2016 .Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert opinion on emerging drugs, 21(1) : 103-16.
Dartois VA,Rubin EJ .2022 .Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nature Reviews Microbiology, 20(11) : 685-701.
Sotgiu G,Tiberi S,D'Ambrosio L,Centis R,Zumla A,Migliori GB .2016 .WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. The Lancet, 387(10037) : 2486-7.
Drlica K,Malik M. Fluoroquinolones .2003 .: action and resistance. Current topics in medicinal chemistry, 3(3) : 249-82.
Lungu I-A,Moldovan O-L,Biriș V,Rusu A .2022 .Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance. Pharmaceutics, 14(8) : 1749.
Sterling T. .2016 .Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 20(12) : S42-S7.
Organization WH .2019 .WHO consolidated guidelines on drug-resistant tuberculosis treatment. , : .
Castro RA,Ross A,Kamwela L,Reinhard M,Loiseau C,Feldmann J .2020 .The genetic background modulates the evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis. Molecular biology and evolution, 37(1) : 195-207.
Kanji A,Hasan R .2019 .Efflux pump as alternate mechanism for drug resistance in Mycobacterium tuberculosis. Indian Journal of Tuberculosis, 66(1) : 20-5.
Ma Z,Lienhardt C .2009 .Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clinics in chest medicine, 30(4) : 755-68.
Larkins-Ford J,Aldridge BB .2023 .Advances in the design of combination therapies for the treatment of tuberculosis. Expert opinion on drug discovery, 18(1) : 83-97.
Daina A,Michielin O,Zoete V. .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports, 7(1) : 42717.
Pires DE,Blundell TL,Ascher DB .2015 .pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of medicinal chemistry, 58(9) : 4066-72.
Trott O,Olson AJ .2010 .AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2) : 455-61.
Studio BD .2020 .. , : .
Wildman SA,Crippen GM SA .1999 .Prediction of physicochemical parameters by atomic contributions. Journal of chemical information and computer sciences, 39(5) : 868-73.
Ertl P,Rohde B,Selzer P .2000 .Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. Journal of medicinal chemistry, 43(20) : 3714-7.
Daina A,Zoete V. .2016 .A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem, 11(11) : 1117-21.
Blower TR,Williamson BH,Kerns RJ,Berger JM .2016 .Crystal structure and stability of gyrasefluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences, 113(7) : 1706-13.
Veber DF,Johnson SR,Cheng H,Smith BR,Ward KW,Kopple KD .2002 .Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 45(12) : 2615-23.
Lipinski CA,Lombardo F,Dominy BW,Feeney PJ .1997 .Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 23(1-3) : 3-25.
Ghose AK,Viswanadhan VN,Wendoloski JJ .1999 .A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of combinatorial chemistry, 1(1) : 55-68.
Egan WJ,Merz KM,Baldwin JJ KM .2000 .Prediction of drug absorption using multivariate statistics. Journal of medicinal chemistry, 43(21) : 3867-77.
Muegge I,Heald SL,Brittelli D. .2001 .Simple selection criteria for drug-like chemical matter. Journal of medicinal chemistry, 44(12) : 1841-6.
Mamada H,Iwamoto K,Nomura Y,Uesawa Y.,Predicting Y. .2021 .-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans. Molecular Diversity, 25 : 1261-70.
Gu Z-F Y-D,Wang T-Y,Cai P-L Y,Deng K-J Y .2024 .Prediction of blood-brain barrier penetrating peptides based on data augmentation with Augur. BMC biology, 22(1) : 86.
Rendic S,Guengerich FP .2015 .Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. , 28(1) : 38-42.
0

Citations

0

Downloads

14

Views